<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="64405">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02267473</url>
  </required_header>
  <id_info>
    <org_study_id>JWGUHMED1-008</org_study_id>
    <nct_id>NCT02267473</nct_id>
  </id_info>
  <brief_title>Hepatitis B Patients Under Oral Nucleos(t)Ide Treatment With Intermittent Assessment of Kidney Function</brief_title>
  <acronym>BONIKA</acronym>
  <official_title>A Multicenter, Prospective, Observational Study of Patients With Chronic Hepatitis B Under Various Oral Nucleos(t)Ide Treatment With Intermittent Assessment of Kidney Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with chronic Hepatitis B who are under oral antiviral treatment for at least 6
      months at study start will be monitored once yearly for kidney function changes within their
      routine outpatient visit. Therefore urine samples will be collected and some additional
      blood test will be done within the routine blood sampling.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This non-interventional, long-term observational cohort study will evaluate demographic,
      clinical, biochemical and virological parameters of outpatients with chronic Hepatitis B who
      are under oral antiviral treatment with an approved Nucleos(t)ide for &gt; 6 months at study
      inclusion.

      During their routine outpatient visits annually an assessment of their kidney function
      especially for a proximal tubular dysfunction will be performed and their comedication will
      be explored. Patients included in the study are followed up for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Kidney Function</measure>
    <time_frame>5 Years</time_frame>
    <description>Reproducible change in creatinine &gt;0.3mg/dl or signs of proximal tubular dysfunction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kidney relevant Comorbidities</measure>
    <time_frame>5 Years</time_frame>
    <description>Proportion of patients with kidney relevant comorbidities like arterial hypertension, diabetes mellitus, gout</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney relevant Comedication</measure>
    <time_frame>5 Years</time_frame>
    <description>Relevance of Comedication e.g. Non Steroidal AntiInflammatory Drugs (NSAIDs) to the kidney function under oral antiviral treatment of chronic Hepatitis B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV-DNS</measure>
    <time_frame>5 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quantitative HBs Antigen</measure>
    <time_frame>5 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitochondrial Toxicity</measure>
    <time_frame>5 Years</time_frame>
    <description>Signs of mitochondrial toxicity under oral antiviral Hepatitis B Treatment like Lipodystrophy or changed fat metabolism</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      spontaneous urine sample to test for proximal tubular function
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic Hepatitis B under oral antiviral treatment with an approved
        Nucleos(t)ice for a minimal duration of 6 months at study inclusion
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  chronic Hepatitis B Virus infection

          -  indication for an antiviral treatment due to the recent german Hepatitis B guidelines
             and oral intake of an approved Nucleos(t)ide for a minimum of 6 months at inclusion

          -  ALT &lt; 2 x UNL (upper normal limit) at study inclusion

          -  age 18 - 89 years

          -  signed informed consent form

        Exclusion Criteria:

          -  coinfection with Hepatitis D Virus (HDV), Hepatitis C Virus (HCV) or Human
             Immunodeficiency Virus (HIV)

          -  Comorbidities that will hinder the study performance (e.g. malignancies, relevant
             psychiatric disorder)

          -  hepatocellular carcinoma or hepatic metastases

          -  legally incapacitated patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Sprinzl, MD</last_name>
      <phone>+49613117</phone>
      <phone_ext>0</phone_ext>
      <email>martin.sprinzl@unimedizin-mainz.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der J. W. Goethe-Universität</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Sarrazin, MD</last_name>
      <phone>+496301</phone>
      <phone_ext>5122</phone_ext>
      <email>sarrazin@em.uni-frankfurt.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <lastchanged_date>October 14, 2014</lastchanged_date>
  <firstreceived_date>October 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospitals</investigator_affiliation>
    <investigator_full_name>Johannes Vermehren</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
